NAFDAC alerts public as US recalls 90,000 bottles of children’s Ibuprofen

By Precious Mark

The National Agency for Food and Drug Administration and Control (NAFDAC) has alerted Nigerians to the recall of about 90,000 bottles of Children’s Ibuprofen Oral Suspension in the United States over concerns of possible contamination with foreign materials.

In a public alert issued on Saturday, NAFDAC said the recall was announced by the United States Food and Drug Administration (USFDA) after consumers reported finding a “gel-like mass” and “black particles” in the medicine.

The affected product, Children’s Ibuprofen Oral Suspension USP (100 mg/5 mL), is commonly used to relieve pain associated with cold, flu, sore throat, headache and toothache, as well as reduce fever in children.

According to NAFDAC, the recalled batches were manufactured by Strides Pharma Inc. in India for Taro Pharmaceuticals U.S.A., Inc. The affected lot numbers are 7261973A and 7261974A, with an expiry date of January 31, 2027.

The agency warned that contaminated medicines could pose health risks, especially to children, including adverse reactions, choking hazards and gastrointestinal complications.

Although the product was distributed and recalled within the United States, NAFDAC said it is taking preventive measures to stop the affected batches from finding their way into Nigeria through authorised or unauthorised channels.

“All NAFDAC zonal directors and state coordinators have been directed to carry out surveillance and mop up the product if found in their areas,” the agency stated.

NAFDAC advised importers, distributors, retailers, healthcare professionals and caregivers to remain vigilant and ensure that medical products are sourced only from licensed suppliers.

The agency also urged hospitals and healthcare facilities to inspect their inventories and immediately quarantine any affected batches discovered.

Parents and caregivers in possession of the recalled product were advised to stop using it and seek medical attention if any unusual reactions are noticed in children who may have taken the medicine.

NAFDAC further encouraged healthcare providers and members of the public to report any adverse drug reactions through its reporting platforms or the nearest NAFDAC office.